Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program | Zendy

Daniel L. Hertz | Zendy; Andrew C. Glatz | Zendy; Amy L. Pasternak | Zendy; Robert J. Lonigro | Zendy; Pankaj Vats | Zendy; YiMi Wu | Zendy; Bailey Anderson | Zendy; Erica Rabban | Zendy; Erika Mora | Zendy; Kevin Frank | Zendy; Dan R. Robinson | Zendy; Rajen Mody | Zendy; Arul M. Chinnaiyan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Integration of Germline Pharmacogenetics Into a Tumor Sequencing Program

Author(s) -

Daniel L. Hertz,

Andrew C. Glatz,

Amy L. Pasternak,

Robert J. Lonigro,

Pankaj Vats,

YiMi Wu,

Bailey Anderson,

Erica Rabban,

Erika Mora,

Kevin Frank,

Dan R. Robinson,

Rajen Mody,

Arul M. Chinnaiyan

Publication year - 2018

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.18.00011

Subject(s) - dpyd , germline , pharmacogenomics , genotyping , medicine , pharmacogenetics , oncology , genotype , genetic testing , germline mutation , genetics , pharmacology , biology , mutation , gene

Evidence-based guidelines inform treatment decisions for patients for whom germline genetic information is available. Our real-time tumor sequencing program, which makes precision treatment decisions for patients with cancer, produces matched germline information, providing a unique opportunity to efficiently implement pharmacogenetics and benefit patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research